Influenza vaccine effectiveness against hospitalized SARS-CoV-2 infection

Ray Lee, Lufeiya Liu, Liyang Yuan, Malcolm Risk, Kevin Heinrich, Martin Witteveen‐Lane, Salim S. Hayek, Ryan E. Malosh, Rodica Pop‐Busui, Jiang Bian, Chen Shen, Dave Chesla, Richard H. Kennedy, Xu Shi, Matthew Sims, Ramin Homayouni, Lili ZhaomedRxiv 2023 · DOI

Abstract

Background: Some studies conducted before the Delta and Omicron variant-dominant periods have indicated that influenza vaccination provided protection against COVID-19 infection or hospitalization, but these results were limited by small study cohorts and a lack of comprehensive data on patient characteristics. No studies have examined this question during the Delta and Omicron periods (08/01/2021 to 2/22/2022). Methods: We conducted a retrospective cohort study of influenza-vaccinated and unvaccinated patients in the Corewell Health East (CHE), Corewell Health West (CHW), and Michigan Medicine (MM) healthcare systems. We used a test-negative, case-control analysis to assess the effectiveness of the influenza vaccine against hospitalized SARS-CoV-2 outcomes in adults, while controlling for individual characteristics, pandemic severity, and waning immunity of the COVID-19 vaccine. Results: Influenza vaccination provided significant protection against SARS-CoV-2 hospitalization across all three systems: CHE (VE=27%), CHW (VE=15%), and MM (VE=50%), with an overall pooled VE of 25% (p<0.001). Conclusion: The influenza vaccine provides a modest degree of protection against severe SARS-CoV-2 infection.

Introduction

Early in the COVID-19 pandemic, preliminary research suggested that the annual influenza vaccine might offer "off-target" or heterologous protection against severe SARS-CoV-2 infection. However, these early findings were often constrained by small sample sizes and the potential for "healthy user bias"—the tendency for health-conscious individuals to seek both influenza and COVID-19 vaccinations while also adhering to other preventive measures. Furthermore, most existing data predated the emergence of the highly transmissible Delta and Omicron variants. This study addresses these gaps by analyzing a large-scale dataset from three major Michigan health systems during the Delta and Omicron waves (August 2021 to February 2022).

Methods and Data Sources

The researchers employed a test-negative, case-control design, comparing patients hospitalized with COVID-19 ("cases") to those with similar symptoms who tested negative ("controls"). This approach helps mitigate biases related to healthcare-seeking behavior.

The study utilized Electronic Health Records (EHR) from three providers: Corewell Health East (CHE), Corewell Health West (CHW), and Michigan Medicine (MM). These records were linked to the Michigan Care Improvement Registry (MCIR) to ensure accurate tracking of both influenza and COVID-19 vaccination statuses.

Summary of data sources and final patient cohorts across the three Michigan healthcare systems.

Statistical analysis involved logistic regression to calculate Odds Ratios (OR) for hospitalization, adjusted for age, race, gender, and the Charlson Comorbidity Index (CCI). Crucially, the model also adjusted for the waning immunity of the COVID-19 vaccine by categorizing the time since the last dose into five distinct windows. To combine data across institutions without compromising patient privacy, a renewable estimation method was used to generate pooled estimates.

Results

The analysis included over 200,000 patients across the three sites. A key challenge in this research is the high degree of overlap between individuals who receive both types of vaccines, which can confound results if not properly modeled.

Venn diagrams illustrating the overlap between COVID-19 and influenza vaccination status among study participants at each site.

Vaccine Effectiveness

The pooled analysis revealed an overall Vaccine Effectiveness (VE) of 25% (OR 0.75, 95% CI: 20-30%) against COVID-19 hospitalization. While protection was consistent across sites, the magnitude varied:

  • Michigan Medicine (MM): 50% VE
  • Corewell Health East (CHE): 27% VE
  • Corewell Health West (CHW): 15% VE

Impact of COVID-19 Vaccination and Demographics

The study confirmed that COVID-19 vaccine protection wanes significantly over time, dropping from ~86% effectiveness within 90 days to statistically non-significant levels after one year. Despite this waning, the "bonus" protection from the flu shot remained significant. Demographic analysis showed that the risk of hospitalization was higher for males (OR 1.33) and increased dramatically with age, particularly for those 65 and older (OR 7.44 compared to those under 30).

Discussion and Conclusion

The observed protection suggests the presence of heterologous immunity, potentially through "trained immunity" where a vaccine reprograms innate immune cells to respond more broadly to various pathogens. While the study rigorously adjusted for comorbidities and vaccination timing, limitations remain, including potential missing EHR data and unmeasured confounders like individual masking behaviors.

In conclusion, this large-scale retrospective study provides evidence that influenza vaccination is associated with a modest but significant reduction in the risk of COVID-19 hospitalization during the Delta and Omicron periods. These findings underscore the broad public health benefits of annual influenza vaccination beyond its primary target.

Summary updated

Abstract

A bstract Background Some studies conducted before the Delta and Omicron variant-dominant periods have indicated that influenza vaccination provided protection against COVID-19 infection or hospitalization, but these results were limited by small study cohorts and a lack of comprehensive data on patient characteristics. No studies have examined this question during the Delta and Omicron periods (08/01/2021 to 2/22/2022). Methods We conducted a retrospective cohort study of influenza-vaccinated and unvaccinated patients in the Corewell Health East(CHE, formerly known as Beaumont Health), Corewell Health West(CHW, formerly known as Spectrum Health) and Michigan Medicine (MM) healthcare system during the Delta-dominant and Omicron-dominant periods. We used a test-negative, case-control analysis to assess the effectiveness of the influenza vaccine against hospitalized SARS-CoV-2 outcome in adults, while controlling for individual characteristics as well as pandameic severity and waning immunity of COVID-19 vaccine. Results The influenza vaccination has shown to provided some protection against SARS-CoV-2 hospitalized outcome across three main healthcare systems. CHE site (odds ratio [OR]=0.73, vaccine effectiveness [VE]=27%, 95% confidence interval [CI]: [18-35], p&lt;0.001), CHW site (OR=0.85, VE=15%, 95% CI: [6-24], p&lt;0.001), MM (OR=0.50, VE=50%, 95% CI: [40-58], p &lt;0.001) and overall (OR=0.75, VE=25%, 95% CI: [20-30], p &lt;0.001). Conclusion The influenza vaccine provides a small degree of protection against SARS-CoV-2 infection across our study sites.
BibTeX
@misc{lee2023influenza,
  author = {Ray Lee and Lufeiya Liu and Liyang Yuan and Malcolm Risk and Kevin Heinrich and Martin Witteveen‐Lane and Salim S. Hayek and Ryan E. Malosh and Rodica Pop‐Busui and Jiang Bian and Chen Shen and Dave Chesla and Richard H. Kennedy and Xu Shi and Matthew Sims and Ramin Homayouni and Lili Zhao},
  title = {{Influenza vaccine effectiveness against hospitalized SARS-CoV-2 infection}},
  year = {2023},
  doi = {10.1101/2023.10.27.23297682},
  howpublished = {medRxiv},
}
Figure